Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.

Launched by CENTRE GEORGES FRANCOIS LECLERC · Aug 12, 2024

Keywords

ClinConnect Summary

The INFOGene study is part of the larger EXOMA2 clinical trial, which aims to understand how cancer patients prefer to receive information about genetic testing that can guide their treatment options. This study focuses on patients with advanced cancer and looks at how well they understand different ways of receiving this important information. By talking with patients at Dijon University Hospital, researchers hope to find the best methods for communicating complex genetic details, making sure that patients fully grasp what the information means for their care.

To participate, patients need to be part of the EXOMA2 study and be comfortable with receiving different types of information. They should speak French and have not previously consulted on genetic testing. Participants will be involved in discussions about their care that may be recorded, helping researchers improve communication between doctors and patients. This study is currently recruiting participants of all genders, aged 65 and older, who are looking to understand more about their cancer treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient identified for inclusion in the EXOMA 2 study (exome analysis request)
• • Available to receive different types of information
• • Fluent in French
• • No prior oncogenetic consultation
• • Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study
• • Authorizing audio recording of consultations and interviews
• Exclusion Criteria:
• • Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)
• • Has a psychiatric, cognitive or neurological disorder that makes participation impossible
• • Working in the field of genetics